PSS12 COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB AND RANIBIZUMAB IN NEOVASCULARAGE-RELATED MACULAR DEGENERATION (AMD)- A CLINICAL AND ECONOMIC COMPARISON OF TWO VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR TREATMENTS
May 1, 2008, 00:00
10.1016/S1098-3015(10)70907-4
https://www.valueinhealthjournal.com/article/S1098-3015(10)70907-4/fulltext
Title :
PSS12 COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB AND RANIBIZUMAB IN NEOVASCULARAGE-RELATED MACULAR DEGENERATION (AMD)- A CLINICAL AND ECONOMIC COMPARISON OF TWO VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR TREATMENTS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70907-4&doi=10.1016/S1098-3015(10)70907-4
First page :
Section Title :
Open access? :
No
Section Order :
666